About Megakaryon
About Megakaryon
Company name
Megakaryon Corporation
Founded
September 9th, 2011
Locations
Kyoto office/Kyoto Lab
Kyoto Research Park
134 Minamimachi, Chudoji,
Shimogyo-ku, Kyoto,
600-8813,
JAPAN
Capitalization
¥100,000,000
Officers
  • Kenichi Akamatsu Kenichi Akamatsu, PH.D.
    CEO,President
  • Tsuyoshi Ayabe Tsuyoshi Ayabe, MBA
    Director,COO＆CFO
  • Asano Asami Asano Asami, Ph.D.
    Director
    Chief Scientific Officer
  • Kenji TsujimotoDirector（Sysmex）
  • Takuro MinamiAudit（Sysmex）
Company Objectives
By utilizing the regenerative potential of induced pluripotent stem (iPS) cells, we aim to produce high-quality platelets and other blood products that are safe, with reliable supply on demand and are affordable while independent of blood donations.
Shareholders
Sysmex Corporation; Genjiro Miwa; Hiromitsu Nakauchi; Kenichi Akamatsu; Otsuka Pharmaceutical Factory, Inc.; Otsuka Pharmaceutical Co., Ltd., SATAKE MultiMix Corporation; iPS Academia Japan, Inc.; iCELL Inc.; Kyoto Seisakusho Co., Ltd.;
Access

Kyoto Research Park

4 minutes walk from Tambaguchi Station on the Sagano Line to Kyoto Research Park.

History

2011

  • September Megakaryon was founded to commercialize the research results of Prof. Nakauchi's research teams that were recognized as an Adaptable and Seamless Technology Transfer Program through Target-driven Research and Development (A-STEP*) project under Japan Science and Technology (JST) Agency.Capital: 10 million.

2013

  • August Additional funding of ￥1,160 million raised through private shares managed by Innovation Network Corporation of Japan, SMBC Venture Capital Co., Ltd., Mizuho Capital Co., Ltd., and Mitsubishi UFJ Capital Co., Ltd.
  • September Kyoto Lab opened at the Kyoto University Hospital Campus.

2014

  • April Cell Processing Center (CPC) completed at the Kyoto Lab.
  • NovemberKyoto office/Kyoto Lab opened in Kyoto.

2015

  • MarchCompany officially recognized as a Designated Core Business within the Kansai National Strategic Special Zone.
  • March Additional ¥2,540 million raised through private shares managed by Innovation Network Corporation of Japan; SMBC Venture Capital Co., Ltd.; Mitsubishi UFJ Capital Co., Ltd.; Mizuho Capital Co., Ltd.; Japan Asia Investment Co., Ltd.; DBJ Capital Co., Ltd.; Nissay Capital Co., Ltd.; KSP, Inc.; and Miyako Capital.
  • November Commenced collaborative research with Harvard University (Boston Children's Hospital)

2016

  • April The Japan Agency for Medical Research and Development (AMED) has recognized our project for "Focused on Developing Key Evaluation Technology: Evaluation for Industrialization in the Field of Regenerative Medicine."
  • May Kyoto Office and Kyoto Lab expansion.

2017

  • June Featured at the Japan-US Innovation Awards Symposium, 2017 held at Stanford　University.
  • December ¥3, 700 million raised through private shares managed by Innovation Network Corporation of Japan; Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc. Sysmex Corporation, CIMIC Holdings Co., Ltd., Kyoto Seisakusho Co., Ltd, Satake Chemical Equipment Mfg Ltd., Shinsei Corporate Investment Ltd., Miyako Capital Co., Mizuho Capital Co., The Shiga Bank Ltd., REVIC Capital Co., Ltd., SMBC Venture Capital Co., Ltd.; Mitsubishi UFJ Capital Co., Ltd.

2018

  • JuneMegakaryon selected for the J-Startup Program.

2020

  • FebruaryMegakaryon Corporation along with the partner companies won the Minister of State for Science and Technology Policy Award at the 2nd Japan Open Innovation contest.
  • FebruaryAdditional ￥2,800 million raised through private shares.

2023

  • AprilMegakaryon Corporation initiates first-in-human clinical trial of allogenic human iPSC-derived HLA homozygous platelets
  • December Megakaryon Corporation has become a consolidated subsidiary of Sysmex Corporation.
pagetop